Premium
Therapeutic Strategies and Pharmacological Tools Influencing S1P Signaling and Metabolism
Author(s) -
Vogt Dominik,
Stark Holger
Publication year - 2017
Publication title -
medicinal research reviews
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.868
H-Index - 130
eISSN - 1098-1128
pISSN - 0198-6325
DOI - 10.1002/med.21402
Subject(s) - fingolimod , sphingolipid , sphingosine , anabolism , sphingosine 1 phosphate , mechanism (biology) , computational biology , pharmacology , sphingosine 1 phosphate receptor , catabolism , signal transduction , function (biology) , biology , bioinformatics , neuroscience , medicine , multiple sclerosis , receptor , microbiology and biotechnology , metabolism , immunology , biochemistry , philosophy , epistemology
During the last two decades the study of the sphingolipid anabolic, catabolic, and signaling pathways has attracted enormous interest. Especially the introduction of fingolimod into market as first p.o. therapeutic for the treatment of multiple sclerosis has boosted this effect. Although the complex regulation of sphingosine‐1‐phosphate (S1P) and other catabolic and anabolic sphingosine‐related compounds is not fully understood, the influence on different (patho)physiological states from inflammation to cytotoxicity as well as the availability of versatile pharmacological tools that represent new approaches to study these states are described. Here, we have summarized various aspects concerning the many faces of sphingolipid function modulation by different pharmacological tools up to clinical candidates. Due to the immense heterogeneity of physiological or pharmacological actions and complex cross regulations, it is difficult to predict their role in upcoming therapeutic approaches. Currently, inflammatory, immunological, and/or antitumor aspects are discussed.